- Akero Therapeutics, Inc. has entered into a definitive agreement to be acquired by Novo Nordisk A/S for up to **$5.2 billion** in cash.  **[1744659_0001193125-25-235919_d42650dex991.htm:0]** 
- Akero shareholders will receive **$54.00 per share in cash** at closing and a non-transferable Contingent Value Right (CVR) of **$6.00 per share** upon full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis due to MASH by June 30, 2031.  **[1744659_0001193125-25-235919_d42650dex991.htm:0]** 
- The upfront cash portion of the consideration, approximately **$4.7 billion**, represents a **19% premium** to Akero's 30-day Volume Weighted Average Price (VWAP).  **[1744659_0001193125-25-235919_d42650dex991.htm:0]** 
- The transaction has been unanimously approved by Akero's Board of Directors and is expected to close around year-end, subject to shareholder and regulatory approvals.  **[1744659_0001193125-25-235919_d42650dex991.htm:0]** **[1744659_0001193125-25-235919_d42650dex21.htm:2]** **[1744659_0001193125-25-235919_d42650d8k.htm:2]**

Akero Therapeutics to be Acquired by Novo Nordisk

- The Ademi Firm is investigating **Akero Therapeutics (NASDAQ: AKRO)** for potential breaches of fiduciary duty and other legal violations concerning its transaction with **Novo Nordisk**.  **[1744659_20251009CG94286:0]** 
- Akero shareholders are set to receive **$54.00 per share**, representing an equity value of approximately **$4.7 billion**.  **[1744659_20251009CG94286:0]** 
- Shareholders will also receive a **contingent value right** entitling them to an additional **$6.00 per share** if Akero's drug efruxifermin receives full U.S. regulatory approval for treating compensated cirrhosis due to MASH by **June 30, 2031**.  **[1744659_20251009CG94286:0]** 
- The investigation also focuses on the conduct of Akero's board of directors, specifically regarding change of control arrangements benefiting insiders and a significant penalty that limits competing bids.  **[1744659_20251009CG94286:0]**

Akero Therapeutics under investigation by Ademi Firm regarding Novo Nordisk transaction

- **Akero Therapeutics** has entered into a definitive agreement to be acquired by **Novo Nordisk A/S** for up to **$5.2 billion** in cash.  **[1744659_342e070c2612420a8c7de49a30d52c34_0]** 
- Akero shareholders will receive **$54.00 per share** in cash at closing and a **Contingent Value Right (CVR) of $6.00 per share**, contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis due to MASH by June 30, 2031.  **[1744659_342e070c2612420a8c7de49a30d52c34_0]** 
- The upfront cash portion of the consideration, approximately **$4.7 billion**, represents a **19% premium** to Akero’s 30-day Volume Weighted Average Price (VWAP).  **[1744659_342e070c2612420a8c7de49a30d52c34_0]** 
- The transaction, unanimously approved by Akero’s Board of Directors, is expected to close around year-end, pending shareholder and regulatory approvals.  **[1744659_342e070c2612420a8c7de49a30d52c34_0]** 
- Akero’s lead product candidate, efruxifermin (EFX), a treatment for metabolic dysfunction-associated steatohepatitis (MASH), will complement Novo Nordisk’s GLP-1 based metabolic treatments.  **[1744659_342e070c2612420a8c7de49a30d52c34_0]** **[1744659_342e070c2612420a8c7de49a30d52c34_1]**

Akero Therapeutics (AKRO)